The Korean Journal of Medicine

  • 제82권3호
  • /
  • Pages.269-273
  • /
  • 2012
  • /
  • 1738-9364(pISSN)
  • /
  • 2289-0769(eISSN)
대한내과학회 (The Korean Association of Internal Medicine)
권호 표지
DOI QR코드

DOI QR Code

결핵의 치료지침

Korean Guidelines for the Treatment of Tuberculosis

  • 박재석 (단국대학교 의과대학 내과학교실)
  • Park, Jae-Seuk (Department of Internal Medicine, Dankook University College of Medicine)
  • 발행 : 2012.03.01
⟨ 이전 논문 다음 논문 ⟩

초록

Tuberculosis (TB) is prevalent and remains a major public health problem in South Korea. Joint committee for the development of Korean guidelines for TB has published a guideline for the treatment of TB recently. The aim of this guideline is to provide evidence based practical recommendations to clinicians caring TB patients in South Korea. Treatment regimen for the newly diagnosed TB is divided into 2 months of initial intensive phase (isoniazid, rifampin, ethambutol, pyrazinamide) followed by 4 months of maintenance phase (isoniazid, rifampin, ethambutol). Ethambutol may be dropped from the regimen after 2 months of treatment if bacilli is susceptible to isoniazid and rifampin (2HREZ/4HR). Because stopping medical treatment by the patient is most serious problem in the treatment of TB, this guideline emphasizes education and supervision of the patients to ensure patient's adherence to taking medicines.

키워드

참고문헌

  1. Joint Committee for the Development of Korean Guidelines for Tuberculosis, Korea Centers for Disease Control and Prevention, Korean Guidelines for Tuberculosis. Seoul: MEDrang Inc., 2011.
  2. World Health Organization. Treatment of Tuberculosis Guidelines. 4th ed. Geneva: World Health Organization, 2010.
  3. Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003;167:603-662. https://doi.org/10.1164/rccm.167.4.603
  4. Lee JH, Chang JH. Drug-resistant tuberculosis in a tertiary referral teaching hospital of Korea. Korean J Intern Med 2001;16:173-179.
  5. Hong YP, Kim SJ, Lee EG, Lew WJ, Bai JY. Treatment of bacillary pulmonary tuberculosis at the chest clinics in the private sector in Korea, 1993. Int J Tuberc Lung Dis 1999;3:695-702.
  6. Kim HJ, Bai GH, Kang MK, et al. A public-private collaboration model for treatment intervention to improve outcomes in patients with tuberculosis in the private sector. Tuberc-Respir Dis 2009;66:349-357. https://doi.org/10.4046/trd.2009.66.5.349
  7. Park JS. Increasing the treatment success rate of tuberculosis in a private hospital through public-private mix (PPM) project. Tuberc Respir Dis 2011;70:143-149. https://doi.org/10.4046/trd.2011.70.2.143

피인용 문헌

  1. Overview of Antibiotic Use in Korea vol.44, pp.4, 2012, https://doi.org/10.3947/ic.2012.44.4.250
  2. Clinical Features of Allergic Bronchopulmonary Aspergillosis in Korea vol.4, pp.5, 2012, https://doi.org/10.4168/aair.2012.4.5.305
  3. Successful desensitization for antitubercular drugs vol.1, pp.4, 2012, https://doi.org/10.4168/aard.2013.1.4.395
  4. Incidences of Serious Infections and Tuberculosis among Patients Receiving Anti-Tumor Necrosis Factor-α Therapy vol.55, pp.2, 2012, https://doi.org/10.3349/ymj.2014.55.2.442
  5. Comparison of tuberculosis incidence in ankylosing spondylitis and rheumatoid arthritis during tumor necrosis factor inhibitor treatment in an intermediate burden area vol.33, pp.9, 2012, https://doi.org/10.1007/s10067-013-2387-z